Lineage Cell Therapeutics

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$2,765
$1,502
$2,868
$3,779
Gross Profit
2,726
1,466
2,714
3,741
EBITDA
-4,769
-6,505
-4,959
-3,699
EBIT
-4,940
-6,669
-5,110
-3,840
Net Income
-30,464
-4,139
-3,273
-3,034
Net Change In Cash
2,765
1,502
2,868
3,779
Free Cash Flow
-5,553
-4,886
-6,711
-5,699
Cash
42,271
47,886
45,789
27,750
Basic Shares
228,356
226,054
200,193
188,835

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$9,499
$8,945
$14,703
$3,896
Gross Profit
9,165
8,274
13,975
2,470
EBITDA
-20,869
-24,041
-21,793
-48,338
EBIT
-21,478
-24,733
-22,520
-49,225
Net Income
-18,609
-21,486
-26,353
-43,019
Net Change In Cash
9,499
8,945
14,703
3,896
Cost of Revenue
-43,468
23,114
Free Cash Flow
-23,657
-29,240
646
-23,915
Cash
45,789
35,442
11,355
55,742
Basic Shares
200,193
172,663
169,792
164,502

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.13
2025-03-31
-$0.02
2024-12-31
-$0.01